Paris, France – December 11, 2025
Cooper Consumer Health and Dr. Reddy’s Laboratories today announced the successful go-live of the Nicotinell® nicotine replacement therapy (NRT) portfolio across France, Spain, Portugal, Belgium and Luxembourg, with commercial operations commencing on December 1, 2025. This milestone follows the Distribution agreement and the earlier launch in Germany and Austria on September 1, 2025.
The go-live marks the completion of a coordinated multi-month transition between Cooper, Dr. Reddy’s and Haleon following Dr. Reddy’s acquisition of the global Nicotinell® brand from Haleon.
Under the partnership agreement, Cooper Consumer Health acts as co-marketer and distributor of the Nicotinell® range in the seven European markets. Cooper will lead in-market distribution, pharmacy activation and commercial execution, leveraging its extensive pan-European footprint and local expertise.
The Nicotinell® range available in these markets includes patches, chewing gums, lozenges and oral sprays. These NRT products help consumers manage cravings and progressively reduce their dependence on nicotine as part of smoking-cessation efforts.
“We are excited to begin this partnership with Dr. Reddy’s and to support the rollout of the Nicotinell® portfolio in these key markets,” said Bart Meermans, CEO of Cooper Consumer Health. “Nicotinell® is a brand with strong heritage in smoking cessation, and our multi-country platform positions us to strengthen its presence and accessibility. Working closely with Dr. Reddy’s, we aim to empower healthier living across the region by broadening reach in pharmacies and retailers, delivering consistent execution, and giving consumers the confidence and products they need to make positive, lasting health decisions.”
“As we transition Nicotinell® into the Dr. Reddy’s portfolio, choosing the right partner in Europe was critical,” said Patrick Aghanian, CEO – Europe Generics & Global Consumer Health, Dr. Reddy’s Laboratories. “Cooper’s scale, strong pharmacy relationships and consistent commercial execution across markets make them an ideal partner. We look forward to working together to expand access to trusted smoking-cessation solutions across Europe.”
About Cooper Consumer Health
Cooper Consumer Health is a leading European consumer healthcare player, focusing on the development, production, and distribution of a diverse range of consumer healthcare brands across most OTC segments. The company serves over +100,000 pharmacies and drugstores across Europe and beyond. It employs +1500 employees across the different European markets.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, committed to accelerating access to affordable and innovative medicines. Established in 1984, the company operates across four key businesses: Global Generics, Pharmaceutical Services & Active Ingredients, Proprietary Products, and Consumer Health. Its diverse portfolio includes APIs, generics, biosimilars, OTC products, and differentiated formulations. Dr. Reddy’s serves major markets including the United States, India, Europe, Russia & CIS, and emerging economies, with therapeutic areas spanning gastrointestinal, cardiovascular, oncology, pain management, and dermatology. Guided by its purpose of “Good Health Can’t Wait,” the company emphasizes quality, compliance, sustainability, and patient-centric innovation to deliver long-term value.
For media inquiries, please contact:
Maxime Giordanengo
Head of Group Corporate Communication
maxime.giordanengo@cooperconsumerhealth.com
